178 related articles for article (PubMed ID: 23803950)
1. Drug development: target practice.
Katsnelson A
Nature; 2013 Jun; 498(7455):S8-9. PubMed ID: 23803950
[No Abstract] [Full Text] [Related]
2. FLT3 inhibitors for acute myeloid leukemia.
Lancet JE
Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
[No Abstract] [Full Text] [Related]
3. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
4. Consistent genetic abnormalities in human cancers as targets for selective therapies.
Clarkson BD
Mt Sinai J Med; 1992 Oct; 59(5):400-4. PubMed ID: 1435835
[No Abstract] [Full Text] [Related]
5. Leukemia.
McKenna SJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Feb; 89(2):137-9. PubMed ID: 10673646
[No Abstract] [Full Text] [Related]
6. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
7. Progress and Prospects in Pediatric Leukemia.
Madhusoodhan PP; Carroll WL; Bhatla T
Curr Probl Pediatr Adolesc Health Care; 2016 Jul; 46(7):229-241. PubMed ID: 27283082
[TBL] [Abstract][Full Text] [Related]
8. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1997; 17():390-407. PubMed ID: 9551222
[No Abstract] [Full Text] [Related]
9. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1999; 18():268-92. PubMed ID: 10800488
[No Abstract] [Full Text] [Related]
10. Novel drug targets in acute leukemia.
Stock W
Clin Adv Hematol Oncol; 2015 Aug; 13(8):493-5. PubMed ID: 26351809
[No Abstract] [Full Text] [Related]
11. Closing in on targeted therapy for acute myeloid leukaemia.
The Lancet Haematology
Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
[No Abstract] [Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
14. [Expression of P27(Kip1) and its clinical significance in acute and chronic leukemia].
Lu RN; Sheng RL; Li JY; Zhu GR; Ding XJ; Zhu LL; Su EB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):291-7. PubMed ID: 15228653
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
16. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
17. Targeted signal transduction therapies in myeloid malignancies.
Scott E; Hexner E; Perl A; Carroll M
Curr Oncol Rep; 2010 Nov; 12(6):358-65. PubMed ID: 20809224
[TBL] [Abstract][Full Text] [Related]
18. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
19. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
[No Abstract] [Full Text] [Related]
20. New Models of Therapy: When Acute Leukemia Becomes Chronic.
Ustun C; Stone R; Weisdorf D
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1856-7. PubMed ID: 26183079
[No Abstract] [Full Text] [Related]
[Next] [New Search]
